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1. Introduction 
Skeletal muscle plays a considerable role in health and disease. Muscle mass is essential for 
health and survival and plays a major role in mobility as well as morbidity and mortality. 
There is continual synthesis and degradation of proteins as part of normal metabolism and 
homeostasis. Equally remarkable, is the characteristic of plasticity allowing muscle to 
change and adapt depending on the stimuli and load placed upon it.  
Increasing the contractile load on skeletal muscle leads to increased muscle mass and 
strength typified by that seen with a resistance exercise programme. This can be beneficial 
for sports performance as well as allowing an individual to improve physical fitness, 
maintain health status and improve quality of life. 
Inactivity, or reduced load, results in a loss of skeletal muscle mass. This loss of muscle mass 
and corresponding loss of strength and function may lead to a reduced quality of life and 
life expectancy [1].  
The morphological changes associated with muscle atrophy are a decreased cross-sectional 
area (CSA) of muscle fibres resulting in a reduced muscle mass, but without a decrease in 
the number of muscle fibres. When the muscle becomes smaller, this leads to reduced 
muscle strength. In humans, muscle atrophy appears to be a consequence of reduced protein 
synthesis with no change in protein degradation [2]. Loss of muscle mass is also seen in 
disease states such as cancer, AIDS, renal failure, congestive heart failure, chronic 
obstructive pulmonary disease (COPD) and burns. In addition to disuse, disease-induced 
muscle loss (cachexia) also involves a complex interplay of cytokine and inflammatory 
responses. 
Disuse is a broad descriptor of the mechanical unloading of the muscle; with the most extreme 
example being that of spaceflight. Far more common life events, such as immobilisation, bed 
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rest or disuse also include decreased mechanical loading. Perhaps most common is the lack 
of regular mechanical loading that accompanies sedentary behaviour. Changes seen with 
disuse/inactivity do not include an increase in inflammatory or cytokine response such as 
that seen in disease state cachexia. 
In this book chapter we will discuss various conditions which lead to skeletal muscle 
atrophy. The excitement generated by spaceflight led many researchers to study 
physiological effects influencing the astronaut who has to function in an atmosphere of no 
gravity. The most common simulation of spaceflight is ground based bed rest. While an 
individual is placed in the horizontal position, the changes noted are not completely 
identical to spaceflight since the astronaut conducts normal daily tasks while the individual 
on bed rest must restrict their movements. Physiological changes during bed rest include 
decreases in muscle mass and strength and other disuse associated changes in skeletal 
muscle. If the bed rest is at a 6o head down tilt angle, the individual will experience 
equivalent fluid shifts to that seen in spaceflight. 
A number of immobilisation techniques have been identified to investigate disuse and load 
reduction on skeletal muscle. Unilateral lower limb suspension (ULLS) involves one limb 
being suspended while the other is used for movement assisted by crutches. Since the 
suspended leg cannot move, muscle mass loss is observed. Similarly, a limb immobilised by 
a leg brace or cast also loses muscle mass due to disuse. 
A rodent model of disuse, hindlimb suspension, also leads to significant skeletal muscle 
atrophy. The model involves the animals supporting their weight on their front legs and 
preventing the back legs from bearing any weight because the animal is suspended by the 
tail. The unloading leads to muscle atrophy and provides a crucial animal model of muscle 
atrophy to provide insight into the complex interplay of influences on skeletal muscle with 
inactivity. 
The extent of muscle atrophy induced by these models has been reported by Narici and de 
Boer [3] and a brief summary is provided here:  
i. Spaceflight: reductions of total lower limb muscle mass of between 6-24%.  
ii. Animal models of disuse: preferential decreases in muscle fibre size are noted in slow 
twitch muscles which are usually consistently more activated due to their postural 
function. 
iii. Unilateral lower limb suspension (ULLS) in humans: 5-10% decrease in quadriceps CSA 
within 4 weeks [4].  
iv. Immobilization (cast or leg brace) in humans: 12% decrease in leg volume with 46% 
decrease in type I fibre size and 37% decrease in type II fibres [5]. 
One of the consequences of a shift in fibre type from slower phenotypes (more oxidative) to 
faster phenotypes (more glycolytic) is the greater fatiguability of the faster fibres. Other 
changes which occur during inactivity and disuse include metabolic alterations including 
reduced insulin sensitivity [6], decreased capillary density in both fibre types and a 
disruption of the skeletal muscle architecture [7].  
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Sarcopenia is the loss of muscle size and strength in the ageing process. There is a gradual 
decrease in physical function throughout the ageing process. Loss of muscle mass in the 
elderly is a significant health risk leading to impairment of maximal aerobic capacity, 
decreased insulin sensitivity, impaired oxidative defense, lower resting metabolic rate and 
functional dependency (reviewed by [8,9]). The mechanisms causing sarcopenia are 
different to those of disuse atrophy even though the reduced activity noted in most elderly 
individuals does contribute to skeletal muscle loss. There are a number of factors which 
contribute to the age-associated decrease in size and strength of skeletal muscle, including 
excessive oxidative stress, degeneration of the neuromuscular junction, fibre 
denervation/reinnervation, decreased oxidative capacity, hypoplasia of type II fibres, 
declining hormone levels, and a fast-to-slow fibre type transition.  
Skeletal muscle changes associated with ageing begin in the 20s and decline more rapidly as 
a person reaches their 50s [10] and this is particularly noted in the lower body [11]. Type II 
fibre size may be reduced by 20-50% and although type I fibres are less affected, they may 
still be 1-25% decreased in size. The reduction in whole muscle mass is greater than muscle 
fibre size reduction because of an additional loss of fibres [10,12]. This phenomenon, not 
seen in disuse atrophy, is a result of progressive degeneration and reinnervation of alpha 
motorneurons. Denervation leads to loss of fibre number (hypoplasia) contributing to 
muscle atrophy. With reinnervation, the previously denervated fibres undergo a change in 
phenotype to the new innervation which results in an increase in number of type I fibres. 
This specific reduction in numbers of type II fibres is associated with increased co-
expression of myosin heavy chain isoforms and fibre grouping ultimately leading to a 
change in recruitment as well as decreased strength. 
Ageing also leads to decreased aerobic capacity, with contributory factors including 
decreases in stroke volume, heart rate and arterio-venous oxygen difference [13]. Together, 
the reduced aerobic capacity and loss of skeletal muscle mass contribute to increased 
morbidity and mortality [14]. Other conditions, also associated with ageing, contribute to 
sarcopenia, loss of function, morbidity and mortality.  
Older adults often have an increased fat mass (sarcopenic obesity) which contributes to 
various metabolic disorders including diabetes, obesity, and cardiovascular disease; and loss 
of bone which causes further mobility reductions because of osteoporosis [15]. The increase 
of fat and non-contractile tissues in the muscle, as well as insulin resistance and reduced 
muscle metabolism, causes the quality of the remaining muscle in an ageing individual to be 
reduced [16]. 
There are many contributing factors to the ageing process which involve hormonal, 
nutritional, immunological and neural components which create a decreased pro-anabolic 
environment and an increased catabolic environment. For example, an increased production 
of cytokines and resulting inflammation. These factors contribute to sarcopenia and result in 
a further reduction in physical activity, decreased basal metabolic rate (BMR), increased risk 
of osteoporosis and increased incidence of falls and injury. 
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An increase in reactive oxygen species (ROS) over the lifespan also has a significant impact 
on the ageing process. As the body ages, an increased production of ROS as well as a 
reduced ability to quench the ROS molecules leads to cellular damage. Further to this 
detriment, there is a decrease in mitochondrial volume as well as reduced functional ability 
of the remaining mitochondria. This, in turn, leads to further increases in ROS production. 
Whereas young muscle is capable of adapting by synthesizing additional enzymes to 
neutralize oxidative stress, this does not occur sufficiently in older adults, thus there is 
accumulation of oxidative damage in the cell contributing to further mitochondrial 
dysfunction and malfunction of other proteins damaged by the free radicals [17]. 
Muscle cells are the most protein dense of all cells and there are mechanisms in place aimed 
at protecting and regenerating healthy muscle tissue. During atrophy, these cellular and 
molecular mechanisms are not able to balance the mechanisms inducing muscle loss.  
The next section of this book chapter aims to elucidate: 
 cellular mechanisms involved in disuse atrophy and sarcopenia including satellite cells, 
and myonuclear domain size. 
 the most relevant molecular pathways: Myostatin/SMAD pathway; ubiquitin 
proteasome pathway and the IGF1/mTOR pathway. 
Thereafter, the rest of the chapter will:  
 Discuss methodological analysis and imaging of skeletal muscle changes with atrophy 
and sarcopenia (including human and animal models). 
 Highlight current knowledge of ways to prevent or alleviate muscle atrophy and 
sarcopenia including exercise and nutritional interventions. 
1.1. Myonuclear Domain and Atrophy/Sarcopenia 
Skeletal muscle cells are large and one of the few cells in the body which are multinucleated. 
Each myonucleus governs a surrounding area of cytoplasm, called a myonuclear domain; and 
muscle fibres are considered to be mosaics of these overlapping myonuclear domains [18]. The 
myonuclear domain theory suggests that each myonucleus produces enough protein to 
support a limited amount of cytoplasm and the structural proteins produced are restricted to 
that domain [19]. If there is need for substantially more proteins, more myonuclei are required, 
thereby establishing new myonuclear domains as fibres increase in size.  
Myonuclei are post-mitotic, but satellite cells can proliferate when required and provide 
new myonuclei to skeletal muscle fibres. Satellite cells are skeletal muscle stem cells which 
reside between the basal lamina and sarcolemma of skeletal muscle fibres. They are required 
for post-natal growth of the fibre [20]. When activated, satellite cells proliferate expressing 
the early myogenic regulatory factors (MRFs), MyoD and Myf5; thereafter they express the 
later MRFs, Myogenin and MRF4, differentiate and donate daughter nuclei to the muscle 
fibre. Satellite cells become activated when adult muscle fibres are stimulated to undergo 
hypertrophy or regeneration [21].  
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The muscle fibre maintains a relatively constant myonuclear domain size during growth 
[22]. Increases in CSA are often accompanied by increases in myonuclei [23,24]. Based on 
this theory, with muscle atrophy there should be a decrease in myonuclear number which 
should correspond with a decrease in CSA, in order to maintain myonuclear domain size. 
Indeed, atrophy due to microgravity is associated with decreased myonuclear number and a 
constant myonuclear domain size [7]. However, recent studies of single fibres suggest that 
nuclear domain may be less consistent than previously thought and it has been suggested 
that fibres undergoing atrophy do not lose myonuclei [25].  After 28 days of denervation, 
nerve impulse block or mechanical unloading there was significant muscle fibre atrophy but 
no loss of myonuclei [26]. 
Results on myonuclear domain maintenance in ageing muscle are equivocal. In atrophied 
muscles, concurrent decreases in fibre size and myonuclear number maintain the 
myonuclear domain size [7]. However, decreases in fibre size without decreases in 
myonuclear number have also been reported in ageing, leading to a reduced myonuclear 
domain size. Hikida et al. [27] showed that the nucleus-to-cytoplasm ratio was not 
maintained in untrained elderly men. In an animal model, Brack et al. [28] found the 
number of nuclei per unit length decreased in ageing animals, which resulted in an 
increased myonuclear domain size. They also found larger fibres to have more satellite cells 
than smaller fibres, but during the ageing process this declined. They postulated that a 
deficit in satellite cells resulted in the inadequate nuclear replacement seen in ageing 
muscle. 
Myonuclear domain size appears to differ between fibre types [29]. Slow fibres have more 
myonuclei per unit area [30], leading to a small myonuclear domain size [7,23,31]. Slow 
fibres have higher rates of protein turnover [32] and a higher oxidative capacity (requiring 
greater levels of protein synthesis) [33]. Fast glycolytic fibres, with lower oxidative activity, 
have relatively larger myonuclear domain sizes [29,31].  
Investigations examining changes in myonuclear domain size in ageing skeletal muscle, at 
least in slow and fast type muscle in rodents, have revealed an increase in number of 
myonuclei in slow fibres resulting in a decrease in myonuclear domain size [34]. This is 
perhaps due to a reduced functional ability of the nuclei in slow fibres of old muscle. It can 
be hypothesised that ageing muscle could benefit from the addition of new myonuclei with 
younger attributes.   
However, research studies examining the effects of ageing on satellite cells also have been 
equivocal. During the ageing process, satellite cells may decrease in number [35–37]. Other 
studies found no reduction in satellite cell numbers in ageing skeletal muscle [27,38]. Similar 
to aged myonuclei, it appears that satellite cells have a decreased functional ability [39,40]. 
But more recent research has shown that this is due to a decrement of factors which 
influence the surrounding milieu, e.g. decreased growth factor levels [41]. This is likely to 
influence the ability of the satellite cells to proliferate and fuse and thus they are unable to 
influence many of the changes seen in sarcopenia, particularly changes in the myonuclear 
domain size.  
 
Skeletal Muscle – From Myogenesis to Clinical Relations 172 
Unlike acute conditions resulting in muscle atrophy, aging and the development of 
sarcopenia occurs slowly. Nevertheless, the myonuclei have independent transcriptional 
ability to respond to local stimuli/signals [42]. In both atrophy and sarcopenia, the molecular 
control of muscle size involves a major negative regulator of muscle mass, as well as other 
pathways, albeit to different extents.  
1.2. The signalling pathways 
The molecular mechanisms underpinning muscle atrophy and ageing remain to be fully 
elucidated. The next section aims to describe a number of key molecular components and 
contributors to atrophy and ageing. In this book chapter we will review current accounts of 
three main contributors – myostatin, ubiquitin ligases MAFbx and MuRF1, and IGF1, AKT-
mTOR pathway.  
1.2.1. Myostatin/SMAD pathway and atrophy/sarcopenia 
Myostatin (growth-differentiation factor 8, GDF8] is a member of the transforming growth 
factor (TGF)β superfamily and a negative regulator of muscle mass. Myostatin appears to be 
primarily found in muscle tissue [43]. Animals with a polymorphism in the myostatin gene, 
that renders it less active, experience hypertrophied muscles. This is seen in “double 
muscled” cattle [44–46], the significant hypertrophy in a child [47]and myostatin knock-out 
mice [43], all of which demonstrate significant hypertrophy in skeletal muscles in response 
to myostatin gene mutation. Even with a normal myostatin gene, if expression is blocked 
experimentally, there are 13-30% increases in skeletal muscle hypertrophy [48]. In 
evolutionary terms, it is well known that hominid size was not the crucial factor securing 
survival. Therefore, adequate control of muscle mass requires that hypertrophy be kept in 
check, and this negative regulator is myostatin.  
Conversely, overexpression of myostatin leads to muscle atrophy [49]. Also, situations of 
muscle disuse in mammals typically lead to increased myostatin mRNA [50] and protein 
[51]. Myostatin inhibits muscle protein synthesis and growth as well as satellite cell 
differentiation [52,53]. 
Members of the TGFβ superfamily, including myostatin, bind to membrane receptors and 
trigger the phosphorylation and activation of the SMADs, a family of signal transducers 
[54]. Myostatin binds to activin type II receptors which results in recruitment of the type I 
receptor to the type II receptor-myostatin complex [55] and activation of regulatory SMADs 
(SMAD2 and SMAD3] [56]. These SMAD2 and SMAD3 complex with SMAD4 and together 
translocate to the nucleus where gene transcription is altered.   
Studies investigating changes in myostatin levels with muscle atrophy have reported: 
i. Spaceflight: increased myostatin transcript levels after 11 days of spaceflight in mice [57].  
ii. Animal models: increased myostatin transcript levels as early as one day after hindlimb 
suspension [58].  
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iii. Bed rest in humans: 25 days of bed rest resulted in 12% greater serum myostatin levels 
[59]. 
iv. Unilateral lower limb suspension (ULLS) in humans: three days of ULLS led to 
increased myostatin transcript and protein levels [60].  
Ageing muscle, again, has shown differing responses. Some authors have reported no 
relationship between myostatin mRNA levels and skeletal muscle mass [61,62] while others 
have shown an increase in myostatin levels along with decreased muscle mass in ageing 
individuals [63,64].  
To unravel the complex differences between atrophy and sarcopenia, it is necessary to 
understand other molecular pathways influencing muscle mass and how these may interact. 
Indeed, myostatin is thought to act through a number of pathways including upregulation 
of ubiquitin-proteasome pathway (including MAFbx and MuRF1]; interactions with FOXO, 
inhibition of AKT-mTOR pathway (see next sections); as well as inhibition of satellite cells 
(described earlier). 
1.2.2. Ubiquitin ligases MAFbx/MuRF1 and atrophy/sarcopenia 
There are various molecular mechanisms involved in muscle wasting including calpain, 
caspase and ubiquitin mediated protein degradation. It is not within the scope of this 
chapter to discuss these in detail, however since the ATP-dependent ubiquitin proteasome 
pathway is the primary degradation pathway of skeletal muscle in response to inactivity 
and disuse, two components of this pathway must be discussed for their role in the 
assessment of the molecular process of skeletal muscle atrophy. The ubiquitin proteasome 
pathway is translationally upregulated during muscle atrophy. It involves E1 ligases which 
activate ubiquitin E2 ligases that are responsible for transferring the activated ubiquitin to 
the protein molecule that is then targeted for degradation, but still requires a further control 
step: the E3 ligases regulate the actual transfer of ubiquitin to the protein. Two important 
skeletal muscle specific ubiquitin E3 ligases are Muscle-specific RING Finger protein1 
(MuRF1] and Muscle Atrophy F-box (MAFbx/atrogin-1]. 
MAFbx and MuRF1 have been identified as factors functioning to a great extent during 
muscle atrophy in several models of disuse [65]. MAFbx and MuRF1 were first identified 
following profiling in mouse atrophy after fasting and immobilisation [65,66]. The expression 
of both appears to be primarily in skeletal muscle. In knock-out models, animals which 
cannot make MAFbx and MuRF1 proteins, do not lose muscle mass with denervation [65].  
MAFbx and MuRF1 mRNA levels are rapidly activated in numerous models of atrophy and 
are thought to contribute to the initiation of the atrophy process [67]: 
i. Spaceflight: increased MAFbx and MuRF1 gene expression in rodents [57] 
ii. Animal models: increased MAFbx and MuRF1 after hindlimb suspension [68] 
iii. Unilateral lower limb suspension (ULLS) in humans: three days of ULLS led to increased 
MAFbx and MuRF1 transcript levels [60]; increased MuRF1 after 10 days ULLS and 
decreased MAFbx and MuRF1 10-21 days of ULLS [69]. 
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iv. Immobilisation (cast or leg brace) in humans: increased MAFbx and MuRF1 gene 
expression after immobilization [70,71]. 
Studies on ageing animals have reported both increased [72] and decreased [73] MAFbx and 
MuRF1 levels. However, in ageing human muscle most studies report no changes in MAFbx 
or MuRF1 [eg [74]]. This may be due to the prolonged nature of the ageing stimulus, or the 
distinct lack of anabolic stimulus.  
MAFbx and MuRF1 are regulated by the family of Forkhead box O (FOXO) transcription 
factors [75]. FOXO1 does not directly increase MAFbx or MuRF1. In rodent muscle, IGF1 
which is pro-anabolic, inhibits the upregulation of these E3-ligases [75], however 
upregulation of FOXO1 blocks this influence of IGF1 and allows for the upregulation of 
MAFbx and MuRF1.  
Nonetheless, human models of atrophy do not show the same relationship of FOXO with 
MAFbx and MuRF1 [eg [60]]. Therefore, to fully understand atrophy and sarcopenia, and 
before discussing the mechanisms behind potential interventions, it is necessary to elucidate 
an anabolic pathway, namely the IGF1-AKT-mTOR pathway.  
1.2.3. IGF1-AKT-mTOR and atrophy/sarcopenia  
Insulin-like growth factor 1 (IGF1] is a critical growth factor that promotes muscle 
hypertrophy in skeletal muscle. IGF1 acts through the AKT-mTOR pathway which plays a 
primarily role in skeletal muscle protein synthesis. IGF1 can stimulate the pathway via PI3K 
and AKT, but ultimately mTOR is the central governing signalling factor which modulates 
transcription via p70S6K, 4E-BP1, eIF4E and thus protein synthesis. When the AKT pathway 
is deactivated this leads to muscle atrophy through FOXO [76]. Animals with knock-out 
AKT genes have significant atrophy. In physiological models of atrophy the following has 
been reported:  
i. Spaceflight: increased FOXO1 transcript levels, decreased insulin receptor substrate-1 
(IRS-1] transcript levels after spaceflight in rodents [57] 
ii. Animal models: 10 days of hindlimb suspension also led to decreased phosphorylation 
of AKT and p70S6K [77]. 
iii. Unilateral lower limb suspension (ULLS) in humans: no change in AKT-mTOR 
pathway components after 10 days or 21 days ULLS [78].  
As mentioned in the previous section, there is an indirect connection between IGF1 and the 
E3 ligases. In cell culture, deactivation of IGF1-PI3K-AKT has been linked to increased levels 
of the ubiquitin proteasome E3 ligases, MAFbx and MuRF1 [79]. It is thought that AKT acts 
directly on FOXO. When growth stimuli are present, AKT acts to phosphorylate FOXO and 
the phosphorylated FOXO remains in the cytosol. When growth stimuli are removed, AKT 
is inactive which causes dephosphorylation of FOXO allowing it to relocate from the cytosol 
to the nucleus and activate genes involved in cell death, cell cycle inhibition and 
metabolism. Animals with overexpression of FOXO have reduced muscle mass and this 
appears to be related to increases in MAFbx and MuRF1. 
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Alterations in IGF1 signalling pathways in older adults contributes to sarcopenia by means 
of influencing muscle fibre size, increased loss of myonuclei and increased proteolysis 
[reviewed in [80]]. Since IGF1 has been shown to control muscle mass in cell culture [81], it’s 
relevance and contribution to age-related changes is fundamental. Indeed, increased total 
AKT (but not phosphorylated AKT) has been reported in ageing adults depicting a 
reduction in efficiency of AKT in older individuals [82].   
Finally, in keeping with the multi-nucleated nature of muscle fibres and the control of 
myonuclear domain size, IGF1 also acts directly on satellite cells. It causes satellite cell 
proliferation and its absence is associated with lower proliferation capacity. Therefore, 
interventions that focus on the IGF1-AKT-mTOR pathway, will also induce activation of the 
support-system for addition of myonuclei.  
2. Methodological analysis and imaging of skeletal muscle changes with 
atrophy and sarcopenia (including human and animal models) 
2.1. Cell Culture 
Cell culture, or in vitro methods, allow researchers to manipulate the environment in which 
the cells will live and grow. The cells are grown under extremely controlled conditions and 
this allows results to be obtained based on absolute control of the system, homogeneity of 
the sample and less compounds needed for analysis. Using cell culture models allows 
removal of confounding variables such as surrounding tissues or the effects of repeated 
stress on an animal or human. It also reduces the use of animals in research. However, 
disadvantages of cell culture include the cost of setting up the laboratories, maintaining the 
cell cultures and adding substances that simulate the controlled physiological conditions to 
the normal culture media. Cell culture provides a great insight into specific pathways (such 
as those discussed earlier) with addition of known major controllers such as myostatin, to 
the media. But this model can also provide evidence of the role of specific proteins and 
pathways by simple removal of specific molecules or the blocking of these by inhibitors or 
silencers.  
Despite all these advantages, within the cell culture models, the cells will not react exactly as 
they would inside mammalian organism. 
2.2. Animal models 
There are a number of well characterized and representative animal models to investigate 
unloading and disuse atrophy, including hindlimb suspension (discussed above).  
Investigations using models of muscle disuse have yielded a large and important body of 
knowledge including details explained in this book chapter. However, it must always be 
remembered that while animal models provide insight and clarification of some of the 
complex signalling pathways and interactions which are underway during muscle atrophy 
and sarcopenia; there are a number of key differences which cast a slight shadow on the 
direct comparison of animal and human models.  
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It is consistently observed and acknowledged that influences on protein synthesis and 
degradation are different in human and animal models, including a faster rate of muscle loss 
in rodent models and a differing response to unloading in slow and fast fibre types in 
animals compared to humans [reviewed in [83]]. In most animal studies investigating 
protein synthesis, the animals had not yet reached maturity and were still in the growth 
phase (albeit slow growth), which is not directly comparable with adult human beings. The 
response of animals to changes which occur with ageing is also not identical to that of the 
human response. A crucial issue that needs to be discussed in this regards, is when the 
ageing response begins in various animal species because this is key to interpretation of 
findings in animal studies. 
Nevertheless, the benefits of animal studies are the insight which they provide for research 
development and strategies that will aid in knowledge development leading to clinical 
studies to prevent or alleviate skeletal muscle atrophy and improve muscle mass in humans, 
and should therefore not be dismissed. 
2.3. Human models 
The extensive benefit of studying skeletal muscle loss with human research projects is the 
direct applicability of the results with the potential to provide extremely useful information 
for individuals, communities and the greater body of scientific knowledge. Furthermore, 
with the advent of technologically advanced medical imaging facilities, analysis of skeletal 
muscle disuse and sarcopenia can be achieved to a greater degree of accuracy than before, 
and more non-invasively.  
Magnetic resonance imaging (MRI): uses radio frequency pulses over a powerful magnetic 
field to image nuclei of the atoms at any depth inside any body tissue. MRI does not use 
ionizing radiation. The MRI builds two-dimensional images of internal body structures such 
as organs, soft tissue and bone, with good contrast between the tissues. MRI can measure 
loss of muscle mass as well as changes within the muscle such as fat infiltration. A further 
advantage is that the images can be stored digitally for later comparison of the same subject 
using the same landmarks. 
Dual-energy X-ray Absorptiometry (DXA): provides an accurate measure of bone mineral 
density, with calculations of fat-free (lean body) and fat mass of an individual. The DXA 
uses two x-ray beams with differing energy levels which create an image of the density of 
different body tissues. After skeletal muscle atrophy, individuals will have a reduction in 
lean body mass and may also have an increased fat mass and alterations in bone mineral 
density. The advantage of this imaging tool is that these concurrent changes in other tissues 
can be assessed at the same time. This is highly relevant since skeletal muscle is not the only 
tissue exposed to the external environmental influences promoting muscle loss.  
Computed Tomography (CT): uses x-rays to show cross-sectional (or slice) images of the body. 
Since the x-ray moves around the body, it provides more detail than a regular x-ray. It can be 
used for diagnostic purposes such as diagnoses of tumors. With disuse and/or sarcopenia the 
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CT scan can measure cross-sectional area of the entire muscle or the muscles in a functional 
group, assess content/quality of the muscle based on protein content/density and measure 
fatty infiltrations and other changes in skeletal muscle occurring with atrophy and disuse. 
Positron emission tomography (PET): looks at how the body functions, rather than the 
body’s anatomy (CT and MRI). After the intake of a radioactive sugar, the PET scan shows 
the metabolic activity of the body and rapidly growing cells. Cells which consume more of 
the radioactive sugar will be detected as darker on the PET scan. 
Skeletal muscle biopsies, small muscle samples taken from humans using minimally 
invasive methods under local anaesthetic, can provide substantial insight into molecular 
pathways and alterations in structural components as well as myonuclei and satellite cells 
after disuse and the long-lasting effects of sarcopenia (as discussed above). 
Together, the benefits and discoveries made and clarified in cell culture, animal models and 
in human muscle tissue samples, combined with those gained from imaging in more holistic 
human studies, provide an essential and significant insight into the complex interplay of 
interactions within skeletal muscle with disuse and sarcopenia. Furthermore, the knowledge 
gained with these experimental techniques will provide an appreciation and clarification of 
ways to intervene to alleviate, reduce or treat skeletal muscle atrophy and sarcopenia. 
3. Prevention and/or alleviation with nutritional and exercise 
interventions 
Because of the complex interplay of neural, hormonal, physical and nutritional alterations 
which occur with both atrophy and sarcopenia, as well as the progress being made in 
understanding molecular and cellular pathways with atrophy and sarcopenia, there are 
numerous potential interventions which can be, and which have been, investigated to 
combat, alleviate or benefit skeletal muscle mass with disuse and ageing. A number of these 
will be discussed here. 
3.1. Exercise 
3.1.1. Resistance exercise 
Resistance exercise increases muscle mass and by increasing the load placed on the muscle 
activates the AKT-mTOR pathway thereby increasing protein synthesis and reducing 
muscle atrophy. As little as one bout of resistance exercise has been reported to increase 
IGF1 gene expression [84]. In young individuals, resistance exercise leads to increased 
protein synthesis after 2-4 hours [85] and this increase is maintained for 24-48 h in untrained 
individuals [85].  
In models of disuse, such as bed rest and immobilization, resistance exercise alone has been 
reported to reduce, but not completely alleviate muscle loss.  Resistance exercise during 14 
days of single leg immobilization was sufficient to preserve quadriceps muscle mass [86] 
and during bed rest exercise alone reduces loss in muscle mass [87].  
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Resistance exercise training appears to be the only consistent way to combat sarcopenia. 
Physical activity can help slow the ageing process and improve the quality of life for 
elderly individuals. Older adults respond well to load bearing activity and increases in 
strength, muscle size and function are repeatedly found with resistance exercise 
interventions even in very old individuals, both community dwelling and nursing home 
residents. Elderly individuals tolerate relatively high intensity resistance exercise and this 
shows the greatest responses. However, care should be taken when prescribing resistance 
exercise for elderly individuals taking into consideration other health complications. 
Resistance exercise training also restores ageing muscle’s ability to increase nuclear 
domain size within hypertrophy [27]. Resistance exercise is thought to affect satellite cells 
and have a positive effect on age-related changes in satellite cells and myonuclei 
[reviewed in [88]]. 
3.1.2. Endurance exercise 
Aerobic exercise such as inflight cycle ergometer in space or endurance exercise on earth 
helps to maintain and improve cardiovascular function [89], however because it has no 
mechanical loading, endurance exercise has no large effect on skeletal muscle mass and 
therefore does not reduce muscle atrophy or sarcopenia. Furthermore, the intensity of the 
endurance exercise must be sufficient to maintain aerobic fitness [90]. Since endurance 
exercise does show positive influences by enhancing muscle oxidative capacity in elderly 
individuals, combining an endurance modality with resistance exercise may add further 
benefits to the muscle. 
3.2. Pharmacological 
3.2.1. Testosterone 
Testosterone has been shown to regulate skeletal muscle mass in humans [91] and anabolic 
steroids are known to increase muscle mass in healthy individuals by increasing protein 
synthesis and accelerating activation of satellite cells and interestingly administration of 
androgens increases satellite cell numbers in a dose-dependent manner [92,93]. This 
response is particularly noted when combined with load bearing exercise. However, 
physiologically relevant increases in testosterone do not appear to enhance protein synthesis 
following resistance exercise [94]. 
During sarcopenia, decreased circulating levels of testosterone and dehydroepiandroste 
(DHEA) are prevalent [95]. Studies have reported a relationship between serum testosterone 
levels and muscle strength in older men. Testosterone alone has shown equivocal results in 
elderly individuals. Increases in lean body mass, but not knee extensor strength has been 
reported [96] However, increases in muscle strength, muscle fibre size and satellite cell 
response after 20 weeks testosterone supplementation are promising in humans [97] and 
mice [98].   
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3.3. Nutritional 
3.3.1. Protein/essential Amino Acids 
Protein synthesis and degradation are influenced by nutrient intake and intake of proteins 
and amino acids (AA) stimulate muscle protein synthesis and inhibits protein breakdown 
[99]. In particular, leucine, an essential amino acid, is an especially powerful stimulator of 
protein synthesis by both insulin dependent and independent pathways. Carbohydrate and 
protein are known to stimulate protein synthesis and can positively influence IGF1-mTOR-
AKT pathway to stimulate protein synthesis and prevent upregulation of FOXO, MuRF1 
and MAFbx; therefore nutritional intake could be a powerful countermeasure in reducing 
muscle mass loss with disuse, particularly in situations where exercise is not feasible (such 
as hospitalized bed rest). 
Essential AA supplementation has been consistently shown to influence protein synthesis 
and alleviate some, but not all, of the loss of skeletal muscle lost with bed rest [100], but not to 
the same extent as exercise. However, 28 days of immobilization with protein and amino acid 
supplementation [28g protein) did not prevent increases in myostatin, MuRF1 or MAFbx 
over time [101].  
The post-absorptive rate of protein synthesis is similar in young and elderly individuals but 
elderly individuals may have a delayed anabolic sensitivity to amino acids compared to 
young individuals [102]. However, elderly individuals can still stimulate muscle protein 
synthesis with increased protein intake, and it also must be noted that many elderly 
individuals do not take in the recommended protein intake and this may contribute further 
to muscle mass loss [103]. Other nutritional interventions have produced positive results 
against sarcopenia, in particular, high quality protein diets may be beneficial for stimulating 
protein synthesis in the muscles of ageing individuals [104].  
3.3.2. Creatine 
Creatine supplementation has been reported to increase energy production, increase fat free 
and muscle mass. It has been reported to improve recovery after immobilization and to act, 
at least in part, through myogenic regulatory factors which influence satellite cells [105] and 
is therefore of interest to reduce muscle loss with clinically related atrophy as well as of 
potential interest in combatting sarcopenia with the elderly population.  
However, older individuals appear to respond differently than young individuals to 
creatine supplementation [106]. Short term creatine supplementation in older adults has 
shown mixed results ranging from no effect [107–109] as well as increased anaerobic power 
and work capacity of sedentary older adults [108]. Short term creatine supplementation also 
has produced increases in strength and fat free mass of elderly men and women [110,111]. In 
longer studies, neither creatine supplementation, protein supplementation, or a combination 
of protein and creatine was shown to provide further benefit beyond 16 weeks of isotonic 
resistance training alone in elderly subjects [112]. However, a recent review on creatine 
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supplementation and elderly individuals suggests that timing and dose may also play a 
critical role in response to supplementation [113]. Since creatine supplementation is a 
natural, inexpensive and as far as we know, safe supplementation; and since creatine 
supplementation may provide other benefits to elderly individuals such as improved 
cognitive ability [114] it continues to be a potential factor in interventions to alleviate 
sarcopenia.  
4. Summary 
In summary, this book chapter has aimed to summarise skeletal muscle changes with disuse 
atrophy and sarcopenia, which are both significant public health issues and potential 
burdens on society. This chapter has introduced and illustrated cellular and molecular 
changes which occur within skeletal muscle, particularly focusing on myonuclei, satellite 
cells, and various relevant signalling pathways including - myostatin/SMADs, ubiquitin 
proteasome pathway and IGF1-AKT-mTOR pathway. The full interactions and molecular 
underpinnings remain to be elucidated, but we have reviewed the current knowledge and 
accounts of these three main contributors. These pathways are complex, and furthermore 
interact with each other in important ways to modulate muscle protein synthesis, muscle 
degradation and maintenance/loss of muscle mass. The significant impact of varying and 
advanced methodological analyses have been reported and the influence of molecular 
analysis, cell culture models, animal models as well as tools to measure interventions in 
human research have been reviewed. Finally, a number of preventative strategies have been 
discussed which are promising for minimising muscle atrophy and sarcopenia. The 
combination of nutritional and pharmacological interventions combined with exercise are 
favourable, practical and feasible applications to successfully influence prevention and 
alleviation of atrophy and sarcopenia. Understanding the disuse-related changes and age-
related declines in muscle mass will provide insight into preventing and combatting 
sarcopenia. This will benefit by improving quality of life in the increasing numbers of 
elderly individuals as well as reducing the burden on the community and the healthcare 
system.  
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